The Only Two Placebo-Controlled Microdosing Trials Found Nothing
A systematic review pulled together every usable study on psilocybin microdosing and found something the enthusiasm has outrun. Two of the eleven studies were placebo controlled. Neither showed a significant improvement. News-Medical summarized the review on September 7.
Patients arrive with microdosing questions whether or not a clinic offers it. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The review | A systematic review published in Frontiers in Psychiatry, screening 897 references |
| What was included | 11 studies published between 2018 and 2024, covering 3,262 participants |
| The strongest evidence | Only two placebo-controlled trials existed, and neither found significant improvement |
| The rest | Mostly cross-sectional surveys and qualitative reports, with high risk of bias |
| Who was studied | Roughly 70 percent male, with no standardized dosing across studies |
| What could not be ruled out | Expectancy and placebo effects, because blinding was inadequate in most studies |
What a Systematic Review Does
This is not a new experiment. It is a structured attempt to find every study on a question and weigh them by quality.
The authors screened 897 references and kept 11. They did not run a meta-analysis. The studies measured too many different things, in too many different ways, to pool.
That heterogeneity is itself a finding. Seven separate outcome domains appeared across the literature, from well-being to creativity to enhanced senses, with no shared measurement.
The Two Trials That Count
Of the 11 studies, only two were placebo controlled. Those are the only ones designed to separate the drug from the expectation of taking it.
Neither showed significant improvement.
Everything else in the evidence base is cross-sectional survey work, case reports or qualitative interviews. Those designs can describe what people believe happened. They cannot establish that a substance caused it.
Why Microdosing Is Especially Vulnerable Here
The dose is defined by being below the threshold of noticeable effect. That is the entire premise.
It also makes the placebo problem unusually severe. A participant who cannot feel anything has nothing to go on except expectation. People who microdose have generally chosen to.
The review names this directly, noting that inadequate blinding leaves the contribution of expectancy unresolved.
The Sample Has a Skew
Participants across the included studies were roughly 70 percent male.
Dosing protocols were not standardized. Different studies used different amounts, different schedules and different preparations, which is part of why pooling was impossible.
Adverse event reporting was sparse. Absence of reported harm here is not evidence of safety. Most of these studies were not built to capture it.
What This Does Not Say
It does not say microdosing does nothing. It says the well-controlled evidence has not shown a benefit yet, which is a different claim.
Eleven studies is a thin base. Two placebo-controlled trials is thinner still, and null results in small trials are not proof of absence.
The honest summary is that this remains an open question with far more enthusiasm than data behind it.
What to Tell a Patient Who Asks
Patients ask about microdosing constantly, usually having read something enthusiastic. The useful answer is specific rather than dismissive.
The surveys reporting benefit are real, and so is the fact that they cannot separate the drug from the expectation. Two trials that did try to separate them found nothing.
A full dose is a different picture, with stronger data and better characterized risks. Oregon’s outcome data showed both.
The Bottom Line
Microdosing has a large cultural footprint and a small evidence base. The gap between those two things is the story.
Our earlier coverage sits in the same place. One study found microdoses improved creative quality but not quantity. We also covered Bryan Johnson’s self-experiment. Neither changes what the controlled trials found.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Psilocybin remains a Schedule I substance under federal law and is not an approved treatment.
